CareDx, Miromatrix Collaborate To Advance Research Using Bioengineered Organs For Human Transplantation

CareDx, Inc. and Miromatrix Medical Inc. have announced an exclusive collaboration to advance the next wave of innovation by using fully transplantable human bioengineered organs. CareDx will create an innovative testing solution for Miromatrix to use in pre-clinical animal models, and will be the sole provider of donor-derived cell-free DNA (dd-cfDNA) testing services for use in human clinical studies to assess acute allograft rejection in Miromatrix's pipeline of human bioengineered organs.

"Through this collaboration with Miromatrix, we are committed to being at the forefront of driving the next wave of innovation to address the organ supply shortage in transplantation." "We hope that one day, bioengineered organs will be a reality for the thousands of patients who are currently waiting for a life-saving organ," said Reg Seeto, CEO and president of CareDx.

"We are honoured to collaborate with Miromatrix, a pioneer in human bioengineered organ development, as they apply our expertise to advance their clinical pipeline." "CareDx is at the forefront of transplant innovation and has been instrumental in driving paradigm shifts in clinical practise through their non-invasive testing services, which are widely used by leading organ transplant centres across the US," said Miromatrix CEO Jeff Ross, Ph.D. "Our collaboration with CareDx enables us to tap into their expertise in ways that may assist us in accelerating our momentum as we drive the next wave of innovation with bioengineered alternatives for use in human organ transplants."

More than 100,000 people in the United States are estimated to be waiting for an organ transplant, but only slightly more than half of them are expected to receive one within the next five years. It is estimated that 17 people per day die while awaiting an organ transplant. CareDx, Inc. is a leading precision medicine solutions company based in Brisbane, California, dedicated to the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and carers. Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives.